Ibrutinib added to Standard-of-Care Therapy improves PFS by 50% for Older Patients with Newly Diagnosed Mantle Cell Lymphoma
The SHINE study is the first international phase III trial to demonstrate a positive impact of ibrutinib combined with standard-of-care treatment in Mantle Cell Lymphoma. The progression-free survival is substantially longer than the common treatment options used today.